Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

Myasthenia Gravis

Myasthenia Gravis

Feb 04, 2019


Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuromuscular junction (NMJ). These proteins include the nicotinic Acetyl Cholinesterase (AChR) or, less frequently, a muscle-specific tyrosine kinase (MuSK). 

To get a free sample report, click the link: https://www.delveinsight.com/report-store/myasthenia-gravis-market-insight-epidemiology-and-market-forecast

Downloads

Article in PDF

Recent Articles
  1. FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $...
  2. Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis
  3. Biogen’s Aduhelm; FDA Approves Sanofi’s Enjaymo; NHS & Orchard Signs a Deal; Bri...
  4. Evaluating the Upcoming Drugs in Pipeline for Major Autoimmune Diseases
  5. Merck’s Keytruda Wins Another FDA Approval; Sanofi Pauses Trial of Myasthenia Gravis Drug, tolebr...
fcrn-inhibitors-in-20-indications
Articles

FcRn Inhibitors Being The Fastest Growing Class, Plans To Get Explored In 20+ Indications

pharma-news-for-astrazeneca-daiichi-sankyo-basilea-genmab
Notizia - Recent Pharma, Healthcare and Biotech Happenings

AstraZeneca and Daiichi Sankyo’s Enhertu US Approval; Basilea’s ZEVTERA FDA Approval; Genmab’s ProfoundBio Acquisition; Rocket Pharmaceuticals’ RP-L102 EMA Approval; Alexion’s Ultomiris and Soliris AAN 2024 Data

Pharma News for Eisai, Biogen, Merck, BMS, Kyverna
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Eisai Submits Marketing Authorization Application for Tasurgratinib; CHMP Issues Positive Opinion for Biogen’s SKYCLARYS; European Commission Approves Merck’s KEYTRUDA + Chemotherapy HER2-ve Gastric or GEJ Adenocarcinoma; BMS Provides Update on RELATIVITY-123 Trial; Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101; Verrica and Torii Pharma Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208

myasthenia gravis
myasthenia gravis (MG)
Myasthenia Gravis market
Myasthenia Gravis market forecast
Myasthenia Gravis market trends
loader